MicroRNA-155 regulates casein kinase 1 gamma 2: a potential pathogenetic role in chronic lymphocytic leukemia
| Autor: | Erica B. Bhavsar, Tuo Zhang, Richard R. Furman, Paul Hakimpour, N Papavasiliou, Zhengming Chen, J K Davidson-Moncada, Piali Mukherjee, Wayne Tam |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Chronic lymphocytic leukemia Biology 03 medical and health sciences 0302 clinical medicine Immune system BCL9 immune system diseases hemic and lymphatic diseases microRNA medicine Humans RNA Neoplasm Letter to the Editor Casein Kinase I Germinal center Hematology Cytidine deaminase medicine.disease Leukemia Lymphocytic Chronic B-Cell Lymphoma Neoplasm Proteins Leukemia MicroRNAs 030104 developmental biology Oncology 030220 oncology & carcinogenesis Immunology |
| Zdroj: | Blood Cancer Journal |
| ISSN: | 2044-5385 |
| Popis: | Chronic lymphocytic leukemia (CLL) is the most common leukemia of adults in Western countries. There are approximately 19 000 new cases diagnosed in the United States in 2016 (https://seer.cancer.gov/statfacts/html/clyl.html). MicroRNAs (miRs) have been implicated as one of the key contributors in the pathogenesis of CLL. One of these miRNAs is miR-155, which is probably the best-characterized miRNA involved in B-cell maturation and function. MiR-155 has a critical role in normal immune function,1 including innate response, regulation of the germinal center response and formation of class-switched plasma cells and negative regulation of activation-induced cytidine deaminase. However, miR-155 is also an oncogenic miRNA overexpression of miR-155 in mice or its precursor BIC in chickens led to the development of lymphomas. Furthermore, abnormal expression of miR-155 has been observed in a number of lymphoid malignancies, including diffuse large B-cell lymphoma, classical Hodgkin lymphoma, primary mediastinal B-cell lymphoma and CLL.2 In various studies, miR-155 has been found consistently overexpressed in CLL cells compared with normal B cells. Although there does not appear to be definitive correlations between miR-155 expression levels and individual CLL prognostic factors, high pretreatment levels of miR-155 in CLL cells or in plasma have been demonstrated to be associated with shorter need-for-treatment interval and failure to achieve complete response, respectively.3, 4 The association of adverse clinical outcome in CLL with high miR-155 levels appears to be linked to the capacity of miR-155 to enhance the sensitivity of CLL cells to B-cell receptor ligation.5 Thus it is likely that miR-155 has important roles in the pathobiology of CLL. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|